Geode Capital Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,254,317
| Closed | -$19.7M | – | 4651 |
|
|
2024
Q1 | $19.7M | Buy |
1,254,317
+33,009
| +3% | +$508K | ﹤0.01% | 1940 |
|
|
2023
Q4 | $19.7M | Buy |
1,221,308
+84,701
| +7% | +$1.08M | ﹤0.01% | 1930 |
|
|
2023
Q3 | $14.5M | Buy |
1,136,607
+27,202
| +2% | +$375K | ﹤0.01% | 2030 |
|
|
2023
Q2 | $15.6M | Buy |
1,109,405
+43,301
| +4% | +$620K | ﹤0.01% | 2023 |
|
|
2023
Q1 | $16.5M | Buy |
1,066,104
+154,710
| +17% | +$2.58M | ﹤0.01% | 1930 |
|
|
2022
Q4 | $14.9M | Buy |
911,394
+33,701
| +4% | +$548K | ﹤0.01% | 1977 |
|
|
2022
Q3 | $16.2M | Buy |
877,693
+52,087
| +6% | +$817K | ﹤0.01% | 1891 |
|
|
2022
Q2 | $10.9M | Buy |
825,606
+184,342
| +29% | +$2.03M | ﹤0.01% | 2195 |
|
|
2022
Q1 | $5.94M | Sell |
641,264
-142,191
| -18% | -$1.21M | ﹤0.01% | 2702 |
|
|
2021
Q4 | $7.65M | Buy |
783,455
+44,697
| +6% | +$841K | ﹤0.01% | 2629 |
|
|
2021
Q3 | $25.1M | Sell |
738,758
-1,572
| -0.2% | -$50.2K | ﹤0.01% | 1792 |
|
|
2021
Q2 | $27.1M | Buy |
740,330
+36,267
| +5% | +$1.4M | ﹤0.01% | 1768 |
|
|
2021
Q1 | $31.6M | Buy |
704,063
+51,224
| +8% | +$2.38M | ﹤0.01% | 1566 |
|
|
2020
Q4 | $37.3M | Buy |
652,839
+35,552
| +6% | +$2.11M | 0.01% | 1319 |
|
|
2020
Q3 | $31.7M | Buy |
617,287
+166,519
| +37% | +$8.16M | 0.01% | 1187 |
|
|
2020
Q2 | $26.9M | Buy |
450,768
+114,990
| +34% | +$6.15M | 0.01% | 1281 |
|
|
2020
Q1 | $13.8M | Buy |
335,778
+38,958
| +13% | +$2.16M | ﹤0.01% | 1540 |
|
|
2019
Q4 | $18.5M | Buy |
296,820
+12,858
| +5% | +$611K | ﹤0.01% | 1614 |
|
|
2019
Q3 | $9.64M | Buy |
283,962
+67,155
| +31% | +$1.99M | ﹤0.01% | 1962 |
|
|
2019
Q2 | $4.89M | Buy |
216,807
+35,061
| +19% | +$821K | ﹤0.01% | 2410 |
|
|
2019
Q1 | $4.22M | Buy |
181,746
+14,842
| +9% | +$388K | ﹤0.01% | 2429 |
|
|
2018
Q4 | $3.5M | Buy |
166,904
+27,157
| +19% | +$668K | ﹤0.01% | 2442 |
|
|
2018
Q3 | $5.41M | Buy |
139,747
+7,953
| +6% | +$294K | ﹤0.01% | 2308 |
|
|
2018
Q2 | $5.19M | Buy |
131,794
+17,462
| +15% | +$514K | ﹤0.01% | 2302 |
|
|
2018
Q1 | $2.29M | Sell |
114,332
-6,319
| -5% | -$160K | ﹤0.01% | 2690 |
|
|
2017
Q4 | $2.73M | Buy |
+120,651
| New | +$2.36M | ﹤0.01% | 2583 |
|
Other funds holding DCPH
Geode Capital Management's DCPH Position: Q2 2024 in Review
Geode Capital Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 1,254,317 shares — an estimated $19.7M sold.
Geode Capital Management first reported a position in DCPH in Q4 2017 and held it in 26 quarters. The position peaked at $37.3M in Q4 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Geode Capital Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Geode Capital Management sold 1,254,317 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $19.7M.
- Geode Capital Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 26 quarters.
- Geode Capital Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $37.3M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.